Rinvoq

RSS

upadacitinib

Authorised
This medicine is authorised for use in the European Union.

Overview

Rinvoq is a medicine for treating adults with rheumatoid arthritis, a disease that causes inflammation of the joints.

Rinvoq is used for moderate or severe rheumatoid arthritis that cannot be controlled well enough with disease-modifying anti-rheumatic medicines or if the patient cannot take these medicines. It can be used on its own or with methotrexate, another medicine for rheumatoid arthritis.

Rinvoq contains the active substance upadacitinib.

This EPAR was last updated on 29/04/2020

Authorisation details

Product details
Name
Rinvoq
Agency product number
EMEA/H/C/004760
Active substance
Upadacitinib
International non-proprietary name (INN) or common name
upadacitinib
Therapeutic area (MeSH)
Arthritis, Rheumatoid
Anatomical therapeutic chemical (ATC) code
L04AA
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH & Co. KG
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
16/12/2019
Contact address

Knollstrasse 50
67061 Ludwigshafen am Rhein
Germany

Product information

27/03/2020 Rinvoq - EMEA/H/C/004760 - IA/0001

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Rinvoq may be used as monotherapy or in combination with methotrexate.

Assessment history

How useful was this page?

Add your rating
Average
1 rating